Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

StatusRecruiting
PhasePhase 3
SponsorPfizer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 79 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Site details revised at 3 of 93 sites
  2. Primary completion moved earlier from Nov 29, 2031 to Mar 27, 2029 Show 4 more changesShow less
    • Study completion date: Nov 27, 2032 to Oct 30, 2032
    • Eligibility criteria expanded, about 17 words
    • Site details revised at 13 of 93 sites
    • Publications: details revised at 1 of 1 entry
  3. Trial sites expanded: 90 → 93 locationsv77
  4. Site details revised at 1 of 90 sitesv76
  5. Study sites: 91 to 90v75
Show 3 earlier versionsHide 3 earlier versions
  1. Re-verified, no change to tracked fieldsv74
  2. Study sites revised (91)v73
  3. Study sites: 90 to 91v72
  1. Trial sites expanded: 44 → 90 locationsv71
  2. Trial sites reduced: 90 → 44 locationsv70
  3. Study sites revised (90)v69
  4. Study sites: 91 to 90v68
  5. 2 versions Re-verified since Jan 27, 2026, no change to tracked fieldsv66-v67
  6. Study sites: 92 to 91v65
  7. Re-verified, no change to tracked fieldsv64
  8. Study sites: 93 to 92v63
  9. Study sites: 94 to 93v62
  10. Study sites revised (94)v61
  11. Study sites: 92 to 94v60
  12. Study sites: 90 to 92v59
  13. Study sites: 91 to 90v58
  14. Study sites: 92 to 91v57
  15. Site details revised at 2 of 92 sitesv56
  16. Site details revised at 2 of 92 sitesv55
  17. Study sites: 94 to 92v54
  18. Study sites: 95 to 94v53
  19. Site details revised at 1 of 95 sitesv52
  20. Study sites revised (95)v51
  21. Site details revised at 2 of 95 sitesv50
  22. Primary completion date: Apr 29, 2027 to Nov 29, 2031
    • Study completion date: Apr 29, 2027 to Nov 27, 2032
    • Study sites revised (95)
    v49
  23. Study sites: 135 to 95v48
  24. Study sites: 132 to 135v47
  25. Study sites: 130 to 132v46
  26. Study sites: 126 to 130v45
  27. Site details revised at 4 of 126 sitesv44
  28. Study sites: 122 to 126v43
  29. Study sites: 120 to 122v42
  30. Site details revised at 3 of 120 sitesv41
  31. Study sites: 104 to 120v40
  32. Study sites: 102 to 104v39
  33. Study sites: 100 to 102v38
  34. Study sites: 99 to 100v37
  35. Study sites: 97 to 99v36
  36. Study sites: 95 to 97v35
  37. Study sites revised (95)v34
  38. Study sites: 91 to 95v33
  39. Study sites: 88 to 91v32
  40. Study sites: 81 to 88v31
  41. Study sites: 74 to 81v30
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
438 trials monitored
See 32 trials at risk
Migraine
483 trials monitored
See 27 trials at risk
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
Trial Details
NCT Number NCT05156398
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Migraine
Related terms Hyperacusis, Migraine Disorders, Nausea, Photophobia
Enrollment 640 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov